NewAmsterdam Pharma (NAMS) Research & Development (2023 - 2026)

NewAmsterdam Pharma has reported Research & Development for 4 years, with the latest figure at $38.0 million in Q1 2026.

• Quarterly Research & Development fell 15.07% year-over-year to $38.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $135.1 million (down 12.12% YoY) and the FY2025 annual result came in at $141.8 million, down 6.32% from the prior year.
• Research & Development slipped to $38.0 million in Q1 2026 per NAMS's latest filing, from $38.6 million in the prior quarter.
• Over five years, Research & Development peaked at $44.8 million in Q1 2025 and troughed at $27.5 million in Q2 2025.
• A 4-year average of $37.7 million and a median of $38.4 million in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2024 and 2025: Research & Development advanced 11.76% in 2024, then retreated 28.3% in 2025.
• Over 4 years, Research & Development stood at $41.3 million in 2023, then slipped by 15.49% to $34.9 million in 2024, then gained by 10.6% to $38.6 million in 2025, then decreased by 1.52% to $38.0 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $38.0 million, $38.6 million, and $31.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.